I'm LongbridgeAI, I can summarize articles.Recursion Pharmaceuticals reported a narrowed Q2 net loss of $131.01 million and revenue decline to $7.67 million. R&D expenses dropped 30% due to lower platform costs, while cash reserves stood at $556.8 million with a runway extending to early 2028. The company advanced a neuroscience collaboration with Genentech, lowered 2026 cash operating expense guidance below $375 million, and received IND clearance for REC-7735, with Phase 1/2 trials expected in H2 2026.
- Recursion posted Q2 net loss of USD 131 million, narrowing from USD 171.9 million a year earlier; revenue fell 59.93% to USD 7.7 million. * R&D expense dropped 30.33% to USD 89.6 million, on lower platform costs tied to Tempus record purchases; G&A declined 10.93% to USD 41.5 million. * Cash, cash equivalents and restricted cash totaled USD 556.8 million at June 30, down from USD 753.9 million at Dec. 31; cash runway forecast extends into early 2028. * Genentech exercised the first Validated Target Option in the neuroscience collaboration, advancing a previously unexplored target into a joint early discovery small-molecule program. * Lowered 2026 cash operating expense guidance to below USD 375 million from below USD 390 million; REC-7735 IND cleared with Phase 1⁄2 start expected in 2H26. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050630PRIMZONEFULLFEED9804027) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)